Sam Waksal’s ROCK2 biotech Graviton hauls in $35M boost from Enavate

In­vestors are pour­ing more mon­ey in­to a biotech cre­at­ed by in­dus­try vet­er­an Sam Wak­sal, founder of Im­Clone Sys­tems, Kad­mon, MeiraGTx and Équili­bre Bio­phar­ma­ceu­ti­cals, and who has sold mul­ti­ple com­pa­nies to Big Phar­ma.

The lat­est bet, clin­i­cal-stage ROCK2 start­up Gravi­ton Bio­science, has land­ed an ad­di­tion­al $35 mil­lion in fund­ing, com­ing from lead in­vestor Pa­tient Square Cap­i­tal’s Ena­vate Sci­ences, Wak­sal told End­points News on Thurs­day af­ter­noon. He said the in­vest­ment gives Gravi­ton a high­er val­u­a­tion than dur­ing the biotech’s pri­or fi­nanc­ings from Cor­morant, Pon­tif­ax and oth­er undis­closed back­ers, who had pre­vi­ous­ly fund­ed the com­pa­ny with at least $30 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.